China Biomaterial Industry Market Foresight and Investment Strategy Report, 2013-2017
A must-have for enterprise medium to long-term strategic planning
Without deep industry knowledge, it will be difficult to gain any return
English Version:USD7900
Including: Paper back + Electronic Copy + Invoice
Customer Hotline:+86 755 - 82925195 / 82925295
Free Hotline:+86 400-068-7188After-sales Hotline: +86 755-33013088
The Ministry of Commerce of the People's Republic of China designated Qianzhan Industrial Research Institute as the only "regional workstation for dealing with trade friction" in the Guangdong-Hong Kong-Macao Greater Bay Area
Customer Hotline:+86 755 - 82925195 / 82925295
Free Hotline:+86 400-068-7188
0755 - 82925195
400-068-7188
We are aware of that the content of our products have been stolen by some ones who changed the design and used it to deceive customers as it is their own products. Customers who are misled may experience no product received or an incomplete product.
Therefore, Qianzhan Industrial Research Institute encourage you to arrange an in-person visit to our company before you make the purchase.
Qianzhan has the sole copyright of all research reports. We have never had partnership or affiliated with any third party agent. Please recognize the""trademark when purchasing reports.To have better investment return or strategic outcomes, you must have a forward-looking vision. Qianzhan Industrial Research Institute - China's leading industry consulting institutions provide you with all the things you need in business!
* The table of contents and the rest of this report are originally created by Qianzhan. Without any prior written permission, it is prohibited to copy or reproduce in any way. To have better investment return or strategic outcomes, you must have a forward-looking vision!
Table of Contents
Content Summary
Currently, China biomaterial science and project has begun to enter the international advancing level while the biomaterial consumption ranks the third in the world. As China’s economy is continuously increasing, some international top research institutes and top 500 corporations pay more and more attention to China biomaterial market. The biomaterial research and industry development in Japan and South Korea, which are next to China, are showing a strong growth trend. It is predicted that Asia will be the major market for biomaterial in the following years.
Generally speaking, biomaterial refers to biomedical-oriented material and biomedical material. China is a country with over 1.3 billion populations and among which 60 million are the disabled. According to the report of Civil Affairs Department, number of the physically disabled is over 15 million, among which number of the amputee is about 8 million and the Kaschin-Beck's Disease which is caused by rheumatoid disease is millions; number of the CHD patient has exceeded 10 million; number of the cataract blind is about 5 million while that of the tooth defect and anodontia is as high as 300 million to 400 million which is 1/4 to 1/3 of the whole population of China. In spite of this, China is going to be an aging society that number of the elder who is over 60 years old in 2011 is 178 million, which is 13.26% of the whole population. The tissue and organ lesion which is caused by aging needs timely treatment and it requires a large number of high-quality biomedical materials and machinery.
Market space of biomedical materials in China is huge. Presently, localization rate of the domestic commonly used biomedical products, such as disposable products (for example, disposable syringes, infusion sets, blood collection and blood bags), dressing, medical seam (needle) and condom are 80%, 70%, 60% and 90%. Meanwhile, market demand of implanted biomedical products greatly increases. There are 180,000 sets of artificial joints for clinical use, 390,000 sets of spinal implanted device, 190,000 sets of implanted tooth as well as 430,000 sets of coronary stent in 2009. Moreover, potential annual demand of such surgical implanted products is 10 times more than that of the actual usage amount. It requires 50,000 sets of IOL annually according to the state “sight emersion plan”. Domestic annual demand of catheter which implant in the body is 100 million, while that of artificial cardiac valve is about 250,000, pacemaker is about 400,000, artificial joints and vascular stents both are about 500,000 sets. In the meantime, demand of bone substitute materials is increasing. Accordingly, market prospects of biomedical-oriented materials are booming.
As regular biomedical products with low technology content, people pay less attention to it. Still, the biomedical product market accounts 1/4 of the whole medical machinery market, and 1/2 of the whole biomedical material and artificial organ market.
The modern medicine is developing towards the directions like regeneration and reconstruction of damaged human tissues and organs; restore and enhance the physiological functions; personalized and minimally invasive treatment and so on. The traditional lifeless materials of medical metal, macromolecule and biological ceramics cannot meet the need of medical development. There are new opportunities and challenges for biomedical material science and project. It is predicted that in the near future, that the market share of biomedical material will be same as medicine. Therefore, the first imperative is to enhance the clinical applied research and application of biomedical materials, and focus on developing an integrated system which closely connects biomedical materials research, development, production and marketing together.
With decades of investment and supports from government, China biomedical material gets a significant progress in the field of scientific research, among which papers and patent applications that are published in 2009 rank top in the world. In the meantime, there are some industry giants of strength and prospects in China, such as Lepu Medical Technology (Beijing) Co., Ltd., MicroPort Medical (Shanghai) Co., Ltd., Grandhope Biotech Co., Ltd., Weigao Holding Company Limited. and Trauson Holdings Company Limited. Among which the Grandhope Biotech Co., Ltd. is listed on July, 2011. Its business transfers from OEM to Establishment of a wholly-owned manufacturing plant and new product R&D center for oversea corporations. We are confident that China biomedical material industry will be better and better and take an important position in the global market in the near future.
Currently, China biomaterial science and project has begun to enter the international advancing level while the biomaterial consumption ranks the third in the world. As China’s economy is continuously increasing, some international top research institutes and top 500 corporations pay more and more attention to China biomaterial market. The biomaterial research and industry development in Japan and South Korea, which are next to China, are showing a strong growth trend. It is predicted that Asia will be the major market for biomaterial in the following years.
Here, we’d like to express our sincere gratitude to National Statistics Bureau of China, International Information Institute, National Institute of the Ministry of Commerce, National Tsing Hua University Library, Institute of Market Economy of the State Council Development Research Center, and Beijing Qinghua Forward Market Research Center, etc. Thank you so much!
Notice: all the market data, especially the corporation list data in this report is only for business reference. Please don’t take the data for enterprise publicity. Thank you! Or Forward shall not take any responsibility for any consequences!
Qianzhan Business Information Co., Ltd. Industry Research College
Research Team of Biomaterial Industry
The National Bureau of Statistics Foreign-related investigation Permission
National Innovation Company and Dual Software Certified Enterprise
The only DRC desginated Enterprise of the Industry Yearbook
National Ministry of Commerce designated Industrial Early Warning and Monitoring Workstation
Guangdong Province Enterprise of Observing Contract and Valuing Credit
Qianzhan is an industry consulting service provider with national innovation company qualification, independent research and development of industrial big data and Dual Software Certification.
Qianzhan is a consulting and research organization that has been engaged in business consulting for over 16 years in China.
Qianzhan is a consulting service provider with a team of nearly 300 industrial researchers and analysts.
Qianzhan is a consulting service provider with an in-house expert pool of 1200 experts.
Qianzhan is a research and consulting organization that have served 180000 clients and received over positive comments from 100000 of our clients.
Qianzhan is an industry research and consulting organization that has been designated by the highest authority, the DRC, to prepare the yearbook.
Qianzhan is an industry planning and consulting organization that adopts the internationally synchronized SCP scientific analysis model and the perfect industry chain research map to guide the business planning and consulting.
Qizhan is a consulting service organization that helps enterprises to solve the five aspects of industry research, planning, strategic design, capital operation and implementation.
Free Hotline:+86 400-068-7188
Customer Hotline:+86 755 - 82925195 / 82925295
Email Address:service@qianzhan.com
3rd Floor, FIYTA Building West, High Tech South Avenue 1, Nanshan District, Shenzhen, China
Location:Rm.1106, Building 1, Jiayu International Plaza, Songhu Road, Yangpu District,
Shanghai, China
Quality Assured
Offer a forward-looking vision to all of our customers.
Customer Service
We welcome any feedbacks and suggestions to make our customers 100% satisfied.
Qualification Certificates
Having more than 20 qualification certificates, including Innovation Company Certificate and Foreign-related investigation Permission etc.
Customers Testimonials
Thank you for recognizing our high quality products and professional, rigorous and sincere service.